| ★ | Vitiligo Pipeline Update: George Martin, MD, on JAK Inhibitors & Melasma Treatment | | 143 | Estados Unidos | |
| 3 | GP-SOD Plus Targeted Phototherapy Improves Vitiligo Repigmentation | | 249 | Estados Unidos | 62 |
| 4 | Continuous Glucose Monitoring in Type 2 Diabetes, With John Anderson, MD | | 196 | Estados Unidos | 62 |
| 16 | SYNCHRONIZE-1: Survodutide Achieves Significant Weight Loss Versus Placebo | | 174 | Estados Unidos | 58 |
| 7 | All 12 Tegoprubart Recipients Off External Insulin Following Islet Implant in Pilot Study | | 168 | Estados Unidos | 60 |
| 15 | AXIOMATIC-TKR: Milvexian Decouples Thrombosis, Hemostasis in DVT | | 146 | Estados Unidos | 58 |
| 18 | Total Plaque Volume Indicates Patients With 0 CAC May Still be at Risk | | 120 | Estados Unidos | 57 |
| 8 | PROACTIVE-HF: Cordella PA Sensor Improves HF Status Regardless of EF | | 100 | Estados Unidos | 60 |
| 2 | Brensocatib, 1 Year Later: Who Benefits Most? | Mark Metersky, MD | | 98 | Estados Unidos | 65 |
| 14 | Phase 3b Data on Ixekizumab, Tirzepatide for Psoriasis and Overweight, With Mark Lebwohl, MD | | 88 | Estados Unidos | 59 |
| 13 | ZUPREME-1: Petrelintide Reduces Obesity, Maintains Tolerability in Phase 2 Trial | | 81 | Estados Unidos | 59 |
| 12 | SUNRISE: Tezepelumab Shows Meaningful OCS Reduction in Severe Asthma | | 78 | Estados Unidos | 59 |
| 19 | How to Sequence Omalizumab, Dupilumab, and Remibrutinib in CSU | | 74 | Estados Unidos | 57 |
| 5 | Avapritinib's 4-Year Impact on Quality of Life in ISM | Thanai Pongdee, MD | | 73 | Estados Unidos | 62 |
| 6 | 2026 Dyslipidemia Guidelines Redefine Treatment, Monitoring Strategies, With Roger Blumenthal, MD | | 71 | Estados Unidos | 62 |
| 10 | Prior Authorization, Precision Medicine, and Eczema Remission, With Jason Hawkes, MD | | 69 | Estados Unidos | 59 |
| 17 | Addressing Advances and Roadblocks in Lipid Management, With Joseph Saseen, PharmD | | 64 | Estados Unidos | 58 |
| 1 | How Well-Being in Psoriasis is Being Assessed Via WHO-5, With Ulrich Mrowietz, MD | | 56 | Estados Unidos | 67 |
| 11 | Abdominal Pain and Bloating: Recognizing HAE, MCAS, and Eosinophilic GI Disorders | Brian Lacy, MD | | 20 | Estados Unidos | 59 |
| 20 | Time to Minimum Residual C-Peptide As a Predictor of Treatment Efficacy in T1D | | 16 | Estados Unidos | 57 |
| 9 | Should You Test Before Introducing Allergenic Foods? What the Evidence Says | | 11 | Estados Unidos | 60 |